About this trial
Prospective, interventional, open-label, non-controlled, multicentric study in Belgium of Luca, of up to 15 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.
Only one eye per subject can be enrolled.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Given written Informed Consent by subject,
Males or females aged 18 - 85 years, pseudophakic or aphakic,
Willing and able to comply with the schedule for follow-up visits,
Requiring vitreoretinal surgery under local or general anesthesia (conditions include vitreous hemorrhage treatment (with potential clinical conditions including: diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macular pucker),
Disqualifiers
Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator),
BMI (kg/m²) > 40,
Axial length <22 or >26 mm per ocular biometry, inclusive,
Presence of clinically significant ocular inflammation or infection within 30 days of Preop Visit, such as CME, uveitis, etc.,
Trial design
Single group
Treatments tested in this trial
vitreoretinal surgery
DevicePatients undergoing vitreoretinal surgery
Treatment groups
Trial outcomes
Primary outcomes
Safety Outcome
incidence and severity of investigational device-related (definitely or probably) adverse events, for all subjects treated with the study device (Safety Population).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.